Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Meta Platforms Inc (META) vs Revvity Inc (RVTY) Price & Performance

Meta Platforms IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Meta Platforms Inc vs Revvity Inc — how do they compare? Meta Platforms Inc trades at $725.49 (market cap $1.84T), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Meta Platforms Inc is far larger — about 108.4× Revvity Inc's market cap, and Meta Platforms Inc pays the higher dividend (0.29%). Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Revvity Inc for 12 Days on average.

METARVTY
Market Cap
$1.84T$16.98B
Volume
15,887,0491,456,900
Sector
MediaHealth
52-Week High
$777.59$157.36
52-Week Low
$525.72$82.26
Typical Hold Time
127 Days12 Days
Enterprise Value
$1.86T$19.30B
Dividend Yield
0.29%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Meta Platforms Inc

META stock trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend per moving averages, with key support at $719 and resistance at $726. Recent financials reveal strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. The launch of the Muse Spark AI model and a $21B deal with CoreWeave highlight strategic initiatives driving investor optimism, countered by ongoing legal challenges over youth addiction.

The outlook for META remains positive with an 80% analyst buy rating and a consensus price target of $781, suggesting ~8% upside. Key opportunities include AI monetization and robust cash flow growth, while risks involve regulatory lawsuits and high capital expenditures. Investors should weigh strong profitability against legal and competitive pressures in the social media sector.

Revvity Inc

RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).

The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

META
73% Buy27% Sell
Avg holding period · 127 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About Meta Platforms Inc

Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.

Read more on META →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →